Alisertib

Generic Name: Alisertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₀ClFN_₄O_₄

CAS Number: 1028486-01-2

Unique Ingredient Identifier: T66ES73M18

Background: Alisertib is a novel aurora A kinase inhibitor under investigation for the treatment of various forms of cancer.

Indication: For the treatment of various forms of cancer.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Puma Biotechnology will host a conference call on Nov 7, 2024, following Q3 2024 financial results release. The call can be accessed via phone or webcast on their website, with a replay available for 90 days. Puma focuses on cancer care, notably with NERLYNX for HER2-positive breast cancer and alisertib for small cell lung and breast cancers.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy